Literature DB >> 27113865

Quality and clinical supply considerations of Paediatric Investigation Plans for IV preparations-A case study with the FP7 CloSed project.

Sara M Hanning1, Mine Orlu Gul2, Jackie Winslade3, Manuel A Baarslag4, Antje Neubert5, Catherine Tuleu2.   

Abstract

A Paediatric Investigation Plan (PIP) is a development plan that aims to ensure that sufficient data are obtained through studies in paediatrics to support the generation of marketing authorisation of medicines for children. This paper highlights some practical considerations and challenges with respect to PIP submissions and paediatric clinical trials during the pharmaceutical development phase, using the FP7-funded Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit (CloSed) project as a case study. Examples discussed include challenges and considerations regarding formulation development, blinding and randomisation, product labelling and shipment and clinical trial requirements versus requirements for marketing authorisation. A significant quantity of information is required for PIP submissions and it is hoped that future applicants may benefit from an insight into some critical considerations and challenges faced in the CloSed project.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical trials; Clonidine; Formulation; Paediatric Investigation Plan; Paediatrics

Mesh:

Substances:

Year:  2016        PMID: 27113865     DOI: 10.1016/j.ijpharm.2016.04.051

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

1.  The CLOSED trial; CLOnidine compared with midazolam for SEDation of paediatric patients in the intensive care unit: study protocol for a multicentre randomised controlled trial.

Authors:  Antje Neubert; Manuel Alberto Baarslag; Monique van Dijk; Joost van Rosmalen; Joseph F Standing; Yucheng Sheng; Wolfgang Rascher; Deborah Roberts; Jackie Winslade; Louise Rawcliffe; Sara M Hanning; Tuuli Metsvaht; Viviana Giannuzzi; Peter Larsson; Pavla Pokorná; Alessandra Simonetti; Dick Tibboel
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.